Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200 cells/μL while individuals with CD4 <200 cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.
Fabbiani, M., Di Giambenedetto, S., Sali, M., Farina, S., Sansonetti, P., Tamburrini, E., Zileri Dal Verme, L., Delogu, G., De Luca, A., Kelvin, D., Cauda, R., Fadda, G., Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients, <<VACCINE>>, 2011; 29 (16): 2836-2839. [doi:10.1016/j.vaccine.2011.02.020] [http://hdl.handle.net/10807/13712]
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
Fabbiani, Massimiliano;Di Giambenedetto, Simona;Sali, Michela;Sansonetti, Paola;Tamburrini, Enrica;Zileri Dal Verme, Lorenzo;Delogu, Giovanni;De Luca, Andrea;Cauda, Roberto;Fadda, Guido
2011
Abstract
Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200 cells/μL while individuals with CD4 <200 cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
